OncoMatch/Clinical Trials/NCT07197827
A Study of YL242 in Subjects With Advanced Solid Tumors
Is NCT07197827 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including YL242 and YL242; Pembrolizumab for advanced solid tumor.
Treatment: YL242 · YL242; Pembrolizumab · YL242; 5-FU; LV · YL242; Pembrolizumab; 5-FU — This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: HER2 (ERBB2) negative (HER2-negative)
HER2-negative G/GEJ
Disease stage
Required: Stage IV, III
Advanced/unresectable or metastatic solid malignant tumor; locally advanced or metastatic non-sq NSCLC; advanced or metastatic HER2-negative G/GEJ
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anti-tumor therapy
Have received at least one prior line of systemic anti-tumor therapy
Cannot have received: topoisomerase I inhibitor
Exception: intolerance only
Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor
Cannot have received: antibody-drug conjugate
Exception: intolerance only
Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- US-201 · New Haven, Connecticut
- US-202 · Sarasota, Florida
- US-204 · Boston, Massachusetts
- US-206 · Grand Rapids, Michigan
- US-205 · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07197827 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior topoisomerase I inhibitor, antibody-drug conjugate disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify